Clin2
NCT07775313Worth exploringNot yet recruiting

Gene therapy for WHIM syndrome

WHIMWartsHypogammaglobulinemiaImmunodeficiencyMyelokathexis

Treatments studied

Part of Blood & lymphatic, Immune system & allergy, Infections, Skin clinical trials.

This trial tests a one-time gene therapy treatment for WHIM syndrome, a rare immune disorder. It aims to fix the genetic cause to improve your body's ability to fight infections. Your stem cells will be collected, edited in a lab, and given back to you after some chemotherapy to prepare your body.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1/Phase 2
Enrollment
10 people
Ages
3 years to 75 years
Study type
Interventional

Who can take part

  • Age 3 years or older and weigh at least 15 kilograms (about 33 pounds)
  • You must have the specific genetic change (CXCR4-R334X) that causes WHIM syndrome
  • Able to have your stem cells collected through apheresis, a process similar to donating blood
  • Past lab results showing low white blood cell counts (neutropenia) or low antibody levels (IgG) requiring treatment
  • Willing to store samples of your blood and tissue for research, and use effective birth control if you can become pregnant or cause pregnancy

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06851767Enrolling by invitation· Phase 1/Phase 2
Gene therapy for X-linked severe combined immunodeficiency

This trial tests a gene therapy that uses base-edited stem cells to treat X-SCID, a genetic immune disorder. It may help improve immune function and reduce infections in patients who still have low immune cells or severe infections despite previous treatments.

Bethesda, Maryland
NCT01306019Recruiting· Phase 1/Phase 2
Gene therapy for children with severe immune deficiency (XSCID)

This trial tests a one-time gene therapy approach to help children with X-linked SCID (a serious inherited immune disorder) make better immune cells. It’s for people who don’t have a fully matched sibling donor and need long-term follow-up after treatment.

Bethesda, Maryland
NCT06959771Recruiting· Phase 1/Phase 2
Gene therapy for CD40L deficiency (Hyper-IgM syndrome) - single patient study

This trial tests a new gene therapy that uses a person's own blood stem cells and T cells, which are corrected with a gene-editing tool called base editing. It is designed for people with a specific CD40L gene mutation who also have liver problems and portal hypertension. The goal is to see if this treatment can improve their immune system and liver health.

Bethesda, Maryland
NCT07113743Enrolling by invitation· Phase 1/Phase 2
Gene therapy for x-linked chronic granulomatous disease

This trial tests a new gene therapy for X-linked chronic granulomatous disease (CGD), a condition where the immune system cannot fight certain infections. The treatment uses your own blood stem cells, which are modified in the lab to help your body produce working immune cells.

Bethesda, Maryland
NCT06325709Recruiting· Phase 1/Phase 2
Gene editing trial for X-linked chronic granulomatous disease

This trial tests a new gene-editing treatment for men with a specific genetic mutation that causes X-linked chronic granulomatous disease (CGD). The goal is to fix the faulty gene in your own blood stem cells to help your immune system fight infections better.

Bethesda, Maryland
NCT04339777Recruiting· Phase 2
Bone marrow transplant for inherited immune system disorders

This trial studies how well a donor bone marrow (stem cell) transplant works for people with inherited immune system problems (called immune deficiencies). It’s for patients who haven’t improved with usual treatment or don’t have another good option.

Bethesda, Maryland

Hear when a new Warts trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.